XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net revenues $ 3,595 $ 3,887 $ 11,041 $ 11,778
Cost of sales 1,926 2,093 5,839 6,234
Gross profit 1,669 1,794 5,203 5,544
Research and development expenses 175 222 628 723
Selling and marketing expenses 539 597 1,716 1,798
General and administrative expenses 283 291 892 822
Intangible assets impairments 24 21 223 295
Goodwill impairment 0 0 745 0
Other assets impairments, restructuring and other items 36 62 282 227
Legal settlements and loss contingencies 195 3 2,048 113
Other income (2) (25) (88) (73)
Operating income (loss) 419 623 (1,244) 1,638
Financial expenses, net 252 241 721 805
Income (loss) before income taxes 166 382 (1,964) 833
Income taxes (benefit) 107 76 (792) 235
Share in (profits) losses of associated companies, net 1 5 (20) (9)
Net income (loss) 58 302 (1,152) 608
Net income (loss) attributable to non-controlling interests 3 11 (21) 32
Net income (loss) attributable to Teva $ 56 $ 292 $ (1,132) $ 576
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ 0.05 $ 0.26 $ (1.02) $ 0.52
Diluted $ 0.05 $ 0.26 $ (1.02) $ 0.52
Weighted average number of shares (in millions):        
Basic 1,111 1,103 1,109 1,102
Diluted 1,119 1,109 1,109 1,109